Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17484882 | 0.83 | CES2 (0.39) | CES2 | |
| SCHEMBL23447111 | 0.79 | CES2 (0.43) | CES2ALDH1A1TDP1 | |
| SCHEMBL2112265 | 0.79 | HTT (0.42) | CES2HTTALDH1A1PLA2G2CCA1 | |
| SCHEMBL25473045 | 0.78 | POLB (0.41) | CES2ALDH1A1MAPTTDP1 | |
| SCHEMBL816275 | 0.77 | ALDH1A1 (0.42) | HTTALDH1A1PLA2G2CCA1CA2 | |
| SCHEMBL7721225 | 0.77 | HTT (0.41) | CES2HTTALDH1A1PLA2G2CCA1 | |
| SCHEMBL12660072 | 0.77 | CES2 (0.41) | CES2ALDH1A1TDP1 | |
| SCHEMBL9969946 | 0.76 | ALDH1A1 (0.39) | CES2HTTALDH1A1PLA2G2CMAPT | |
| SCHEMBL9969950 | 0.76 | CES2 (0.47) | CES2 | |
| SCHEMBL816653 | 0.76 | TSHR (0.40) | HTTALDH1A1PLA2G2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023083295-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| EP-3235799-B1 | OXIME COMPOUND AND HERBICIDE | NISSAN CHEMICAL CORP (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-11000033-B2 | Ketone or oxime compound, and herbicide | NISSAN CHEMICAL CORPORATION (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20190053488-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL CORPORATION (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| EP-3235799-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | Nissan Chemical Industries, Ltd. (JP) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| WO-2016098899-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | 日産化学工業株式会社 | 2016-06-23 | — | — | WO | disclosed |
| WO-2016016292-A1 | 2-OXA-5-AZABICYCLO[2.2.1]HEPTAN-3-YL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2016015333-A1 | 2-OXA-5-AZABICYCLO [2.2.1] HEPTAN-3-YL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2016-02-04 | — | — | WO | disclosed |
| WO-2012046882-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000033-B2 | Ketone or oxime compound, and herbicide | OR10J3, CYP1B1, CBR3 | CES2 1690/4885HTT 3162/4885ALDH1A1 493/4885 |
| US-20190053488-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | OR10J3, CYP1B1, CBR3 | CES2 1723/4885HTT 3224/4885ALDH1A1 517/4885 |
| US-20170347647-A1 | KETONE OR OXIME COMPOUND, AND HERBICIDE | OR10J3, CYP1B1, CBR3 | CES2 1723/4885HTT 3224/4885ALDH1A1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.